Allovir (NASDAQ:KLRS) Cut to Sell at Wall Street Zen

Allovir (NASDAQ:KLRS) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Monday.

Allovir Stock Performance

Shares of KLRS stock opened at $3.30 on Monday. Allovir has a 52 week low of $2.64 and a 52 week high of $24.15.

Allovir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.